Stoke Therapeutics (NASDAQ:STOK) Price Target Lowered to $20 00 at Canaccord Genuity Group wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.
– Recent data demonstrating reductions in seizure frequency and improvements in cognition and behavior support the potential for STK-001 as a disease-modifying potential medicine for the treatment.
Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a note issued to investors on Monday, Benzinga reports. They currently have a $22.00 price target on the stock. Needham & Company LLC’s price target would indicate a potential upside of 80.33% from the […]
Stoke Therapeutics : Corporate Presentation - May 2024 marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.